| Answers |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Stocks Mutual Funds > Are You Trader Or An Investor? |
|
Answers - Are You Trader Or An Investor?
Firstly what is the difference between a trader and an investor? An investor is us According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ually in for the medium to long term and is looking at a percentage (%) return on h ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in is capital outlay. Be it either shares or property investment. His main concern wou lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. d be the dividend return that the company pays. I f the current price of this asse here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe t declines but the income being generated has remained constant or much the same. T d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro en the investor sees no cause to sell. Now the trader buys an asset at the best pr ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc ice possible. This is with the intent to sell it again at a much higher price. Thes easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi e rewards often come from capital gains. Another factor is time as the investor is nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically in for the long haul whilst the trader is in for the shortest time possible to real and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ise a satisfactory profit. Another difference is their respective understanding of ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi “risk not time.” The biggest difference is how they handle any downturns in the ma ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a rket. The trader seeing a downturn will exit the trade either taking a smaller prof dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod it or a small loss. The smart investor should do the same, but these are in the mi cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ority. What usually happens is the investor believes that his stock selection crite tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ria was correct and hopes that the market will reverse, so therefore he hangs on. t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel nce it becomes apparent that the uptrend is finished it is usually too late to sell ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust because he has lost so much profit or capital, he now cannot afford the loss and d y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products ecides to keep the stock as a long term investment. And hopes one day it will recov . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de r and make money. (Does this ring a few bells or sound familiar?) The trader and i elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip nvestor do have one thing in common and that is they both profit from rising prices tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Impossible - At First Glance the Project Appeared Impossible I Am Shopping For - The Best Way To Sell My Products Online How Do I Make My Very Own Free Website With My Own Domain?
|